LAVA Therapeutics Q1 EPS $(0.02) Beats $(0.12) Estimate, Sales $6.99M Miss $7.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
LAVA Therapeutics (NASDAQ:LVTX) reported a Q1 EPS of $(0.02), beating the $(0.12) estimate, and sales of $6.99M, slightly missing the $7.00M estimate. EPS improved by 96.23% YoY, and sales increased by 471.24% YoY.
May 21, 2024 | 11:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LAVA Therapeutics reported a Q1 EPS of $(0.02), beating the $(0.12) estimate, and sales of $6.99M, slightly missing the $7.00M estimate. EPS improved by 96.23% YoY, and sales increased by 471.24% YoY.
The significant beat on EPS and substantial YoY improvements in both EPS and sales are likely to positively impact LVTX's stock price in the short term, despite the slight miss on sales estimates.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100